Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1064

1.

Immune-mediated neuropathies.

Kieseier BC, Mathey EK, Sommer C, Hartung HP.

Nat Rev Dis Primers. 2018 Oct 11;4(1):31. doi: 10.1038/s41572-018-0027-2. Review.

PMID:
30310069
2.

Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.

Graf J, Ringelstein M, Lepka K, Schaller J, Quack H, Hartung HP, Aktas O, Albrecht P.

Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276. [Epub ahead of print]

PMID:
30307371
3.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
4.

Regional variation of Guillain-Barré syndrome.

Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium .

Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232.

PMID:
30247567
5.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2018 Aug 28. doi: 10.1007/s11682-018-9942-9. [Epub ahead of print]

PMID:
30155789
6.

Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures.

Kraemer M, Karakaya R, Matsushige T, Graf J, Albrecht P, Hartung HP, Berlit P, Laumer R, Diesner F.

J Neurol. 2018 Oct;265(10):2425-2433. doi: 10.1007/s00415-018-9031-4. Epub 2018 Aug 28.

PMID:
30155735
7.

Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy.

Graf J, Jansen L, Ingwersen J, Ringelstein M, Harmel J, Rybak J, Kolbe R, Rhöse L, Gemerzki L, Lee JI, Klistorner A, Guthoff R, Hartung HP, Aktas O, Albrecht P.

Ann Clin Transl Neurol. 2018 Jul 7;5(8):952-961. doi: 10.1002/acn3.593. eCollection 2018 Aug.

8.

Moyamoya angiopathy: early postoperative course within 3 months after STA-MCA-bypass surgery in Europe-a retrospective analysis of 64 procedures.

Kraemer M, Sassen J, Karakaya R, Schwitalla JC, Graf J, Albrecht P, Hartung HP, Diehl RR, Berlit P, Laumer R, Diesner F.

J Neurol. 2018 Oct;265(10):2370-2378. doi: 10.1007/s00415-018-8997-2. Epub 2018 Aug 17.

PMID:
30120561
9.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
10.

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.

Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP.

Lancet Neurol. 2018 Aug;17(8):689-698. doi: 10.1016/S1474-4422(18)30202-3. Epub 2018 Jul 9.

PMID:
30001923
11.

Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.

Leussink VI, Montalban X, Hartung HP.

CNS Drugs. 2018 Jul 10. doi: 10.1007/s40263-018-0536-2. [Epub ahead of print] Review.

PMID:
29992409
12.

[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Aktas O, Wattjes MP, Stangel M, Hartung HP.

Nervenarzt. 2018 Jun 6. doi: 10.1007/s00115-018-0550-0. [Epub ahead of print] Review. German.

PMID:
29876600
13.

150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy.

Lehmann HC, Compston A, Hartung HP.

Neurology. 2018 May 29;90(22):1011-1016. doi: 10.1212/WNL.0000000000005613.

PMID:
29807916
14.

Cerebrospinal fluid findings in reversible cerebral vasoconstriction syndrome: a way to differentiate from cerebral vasculitis?

Kraayvanger L, Berlit P, Albrecht P, Hartung HP, Kraemer M.

Clin Exp Immunol. 2018 Sep;193(3):341-345. doi: 10.1111/cei.13148. Epub 2018 Jul 23.

PMID:
29722896
15.

ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.

Kremer D, Küry P, Hartung HP.

Mult Scler. 2018 May;24(6):696-700. doi: 10.1177/1352458518768770. Epub 2018 Apr 9.

PMID:
29629605
16.

A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.

J Peripher Nerv Syst. 2018 Jun;23(2):108-114. doi: 10.1111/jns.12267. Epub 2018 Apr 26.

17.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

18.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

19.

Human Endogenous Retroviruses in Neurological Diseases.

Küry P, Nath A, Créange A, Dolei A, Marche P, Gold J, Giovannoni G, Hartung HP, Perron H.

Trends Mol Med. 2018 Apr;24(4):379-394. doi: 10.1016/j.molmed.2018.02.007. Epub 2018 Mar 15. Review.

20.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
21.

Teriflunomide promotes oligodendroglial differentiation and myelination.

Göttle P, Manousi A, Kremer D, Reiche L, Hartung HP, Küry P.

J Neuroinflammation. 2018 Mar 13;15(1):76. doi: 10.1186/s12974-018-1110-z.

22.

[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].

Meuth SG, Ruck T, Aktas O, Hartung HP.

Nervenarzt. 2018 Aug;89(8):895-907. doi: 10.1007/s00115-018-0498-0. Review. German.

PMID:
29523912
23.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2018 Mar 1:1352458518763089. doi: 10.1177/1352458518763089. [Epub ahead of print]

PMID:
29521573
24.

Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model.

Dietrich M, Helling N, Hilla A, Heskamp A, Issberner A, Hildebrandt T, Kohne Z, Küry P, Berndt C, Aktas O, Fischer D, Hartung HP, Albrecht P.

J Neuroinflammation. 2018 Mar 7;15(1):71. doi: 10.1186/s12974-018-1111-y.

25.

Progress in Recognizing and Treating Polyneuropathy.

Kieseier BC, Hartung HP.

Dtsch Arztebl Int. 2018 Feb 9;115(6):81-82. doi: 10.3238/arztebl.2018.0081. No abstract available.

26.

Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis.

Ingwersen J, De Santi L, Wingerath B, Graf J, Koop B, Schneider R, Hecker C, Schröter F, Bayer M, Engelke AD, Dietrich M, Albrecht P, Hartung HP, Annunziata P, Aktas O, Prozorovski T.

J Neurochem. 2018 Feb 23. doi: 10.1111/jnc.14324. [Epub ahead of print]

PMID:
29473171
27.

Altered TAOK2 activity causes autism-related neurodevelopmental and cognitive abnormalities through RhoA signaling.

Richter M, Murtaza N, Scharrenberg R, White SH, Johanns O, Walker S, Yuen RKC, Schwanke B, Bedürftig B, Henis M, Scharf S, Kraus V, Dörk R, Hellmann J, Lindenmaier Z, Ellegood J, Hartung H, Kwan V, Sedlacik J, Fiehler J, Schweizer M, Lerch JP, Hanganu-Opatz IL, Morellini F, Scherer SW, Singh KK, Calderon de Anda F.

Mol Psychiatry. 2018 Feb 21. doi: 10.1038/s41380-018-0025-5. [Epub ahead of print]

PMID:
29467497
28.

[Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Löbermann M, Handorn B, Winkelmann A, Reisinger EC, Hartung HP, Zettl UK.

Nervenarzt. 2018 Oct;89(10):1172-1178. doi: 10.1007/s00115-018-0492-6. Review. German.

PMID:
29404651
29.

Acute exacerbations after decades of non-active chronic multiple sclerosis.

Haupts MR, Spill-Askeridis P, Humpert M, Seidel D, Hartung HP.

Mult Scler. 2018 Aug;24(9):1265-1266. doi: 10.1177/1352458518754365. Epub 2018 Jan 24. No abstract available.

PMID:
29363379
30.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
31.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
32.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
33.

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy.

Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, MacKenzie CR, Warnke C, Feldt T, Lammerskitten A, Klotz L, Meuth S, Wiendl H, Hartung HP, Aktas O, Albrecht P.

Ann Clin Transl Neurol. 2017 Nov 24;4(12):909-914. doi: 10.1002/acn3.491. eCollection 2017 Dec.

34.

Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke.

Lee JI, Gliem M, Gerdes G, Turowski B, Kaschner M, Kraus B, Hartung HP, Jander S.

PLoS One. 2017 Dec 27;12(12):e0190218. doi: 10.1371/journal.pone.0190218. eCollection 2017.

35.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
36.

Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.

Sasidhar MV, Chevooru SK, Eickelberg O, Hartung HP, Neuhaus O.

PLoS One. 2017 Dec 18;12(12):e0189701. doi: 10.1371/journal.pone.0189701. eCollection 2017.

37.

A Standardized Clinical Pathway to Decrease Hospital Admissions Among Febrile Children With Sickle Cell Disease.

Ellison AM, Smith Whitley K, Kittick M, Schast A, Norris C, Hartung H, McKnight T, Coyne E, Lavelle J.

J Pediatr Hematol Oncol. 2018 Mar;40(2):111-115. doi: 10.1097/MPH.0000000000001052.

PMID:
29252940
38.

NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody.

Malviya M, Barman S, Golombeck KS, Planagumà J, Mannara F, Strutz-Seebohm N, Wrzos C, Demir F, Baksmeier C, Steckel J, Falk KK, Gross CC, Kovac S, Bönte K, Johnen A, Wandinger KP, Martín-García E, Becker AJ, Elger CE, Klöcker N, Wiendl H, Meuth SG, Hartung HP, Seebohm G, Leypoldt F, Maldonado R, Stadelmann C, Dalmau J, Melzer N, Goebels N.

Ann Clin Transl Neurol. 2017 Oct 3;4(11):768-783. doi: 10.1002/acn3.444. eCollection 2017 Nov.

39.

Late age onset of amyotrophic lateral sclerosis is often not considered in elderly people.

Broussalis E, Grinzinger S, Kunz AB, Killer-Oberpfalzer M, Haschke-Becher E, Hartung HP, Kraus J.

Acta Neurol Scand. 2018 Mar;137(3):329-334. doi: 10.1111/ane.12869. Epub 2017 Nov 17.

PMID:
29148035
40.

Fulminant intramedullary spinal cord sarcoidosis.

Graf J, Ringelstein M, Aktas O, Wattjes MP, Hartung HP.

Mult Scler Relat Disord. 2017 Nov;18:47-48. doi: 10.1016/j.msard.2017.09.010. Epub 2017 Sep 13.

PMID:
29141820
41.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Erratum in: Lancet Neurol. 2018 Jan;17 (1):26. Lancet Neurol. 2018 Aug;17(8):661.

PMID:
29122523
42.

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.

Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F.

Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317732802. doi: 10.1177/2055217317732802. eCollection 2017 Oct-Dec.

43.

Human mesenchymal factors induce rat hippocampal- and human neural stem cell dependent oligodendrogenesis.

Jadasz JJ, Tepe L, Beyer F, Samper Agrelo I, Akkermann R, Spitzhorn LS, Silva ME, Oreffo ROC, Hartung HP, Prigione A, Rivera FJ, Adjaye J, Küry P.

Glia. 2018 Jan;66(1):145-160. doi: 10.1002/glia.23233. Epub 2017 Sep 22.

PMID:
28940767
44.

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC.

Neurology. 2017 Oct 10;89(15):1584-1593. doi: 10.1212/WNL.0000000000004485. Epub 2017 Sep 15.

45.

CIDP and other inflammatory neuropathies in diabetes - diagnosis and management.

Rajabally YA, Stettner M, Kieseier BC, Hartung HP, Malik RA.

Nat Rev Neurol. 2017 Oct;13(10):599-611. doi: 10.1038/nrneurol.2017.123. Epub 2017 Sep 15. Review.

PMID:
28914883
46.

Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.

Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H.

Drugs. 2017 Oct;77(16):1755-1768. doi: 10.1007/s40265-017-0814-1.

47.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

48.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

49.

Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.

Ehler J, Blechinger S, Rommer PS, Koball S, Mitzner S, Hartung HP, Leutmezer F, Sauer M, Zettl UK.

Int J Mol Sci. 2017 Aug 11;18(8). pii: E1749. doi: 10.3390/ijms18081749.

50.

Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.

Warnke C, Graf J, Hartung HP.

Mult Scler. 2017 Aug;23(9):1176-1178. doi: 10.1177/1352458517720045. No abstract available.

PMID:
28749310

Supplemental Content

Loading ...
Support Center